Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma

Published:2015-07 Issue:7 Volume:78 Page:400-407
ISSN:1726-4901
Container-title:Journal of the Chinese Medical Association
language:en
Short-container-title:

Author:

Yang Sheng-Hsiang,Hsiao Liang-Tsai,Chiou Tzeon-Jye,Yang Ching-Fen,Yu Yuan-Bin,Liu Chun-Yu,Gau Jyh-Pyng,Liu Jin-Hwang,Chen Po-Min,Tzeng Cheng-Hwai

Funder

Taiwan Clinical Oncology Research Foundation

Taipei Veterans General Hospital

National Science Council

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Major impact of prognosis by age and sex in patients with primary mediastinal large B‑cell lymphoma;Oncology Letters;2023-12-13

2. Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results;Hematological Oncology;2017-01-12

3. Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients;Hematological Oncology;2016-10-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP